Trial · NCT04427501
Participant flow72
How many started, completed or left each group, period by period.
1 to 20 of 72
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase 2: Placebo | 156 | |
| Overall Study | STARTED | Phase 2: 700 mg Bamlanivimab | 101 | |
| Overall Study | STARTED | Phase 2: 2800 mg Bamlanivimab | 107 | |
| Overall Study | STARTED | Phase 2: 7000 mg Bamlanivimab | 101 | |
| Overall Study | STARTED | Phase 2: 2800 mg Bamlanivimab + 2800 mg Etesevimab | 112 | |
| Overall Study | STARTED | Phase 3: Placebo | 776 | |
| Overall Study | STARTED | Phase 3: 2800 mg Bamlanivimab + 2800 mg Etesevimab | 518 | |
| Overall Study | STARTED | Phase 3: 700 mg Bamlanivimab + 1400 mg Etesevimab | 513 | |
| Overall Study | STARTED | Phase 3: Placebo For 350 mg Bamlanivimab + 700 mg Etesevimab | 141 | |
| Overall Study | STARTED | Phase 3: 350 mg Bamlanivimab + 700 mg Etesevimab | 213 | |
| Overall Study | STARTED | Phase 2/3: Bamlanivimab + Etesevimab (Pediatric Addendum, Arm 22) | 94 | |
| Overall Study | STARTED | Phase 2/3: Bebtelovimab (Pediatric Addendum, Arm 23) | 17 | |
| Overall Study | Received at Least One Dose of Study Drug | Phase 2: Placebo | 156 | |
| Overall Study | Received at Least One Dose of Study Drug | Phase 2: 700 mg Bamlanivimab | 101 | |
| Overall Study | Received at Least One Dose of Study Drug | Phase 2: 2800 mg Bamlanivimab | 107 | |
| Overall Study | Received at Least One Dose of Study Drug | Phase 2: 7000 mg Bamlanivimab | 101 | |
| Overall Study | Received at Least One Dose of Study Drug | Phase 2: 2800 mg Bamlanivimab + 2800 mg Etesevimab | 112 | |
| Overall Study | Received at Least One Dose of Study Drug | Phase 3: Placebo | 776 | |
| Overall Study | Received at Least One Dose of Study Drug | Phase 3: 2800 mg Bamlanivimab + 2800 mg Etesevimab | 518 | |
| Overall Study | Received at Least One Dose of Study Drug | Phase 3: 700 mg Bamlanivimab + 1400 mg Etesevimab | 513 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04427501/flow